An observational study in Metabolic Dysfunction-associated Fatty Liver Disease, sponsored by The First Affiliated Hospital of Zhejiang Chinese Medical University. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-29.
Sponsored by The First Affiliated Hospital of Zhejiang Chinese Medical University · Observational
This is a case-control study that aims to build a predictive model for MAFLD based on machine learning.
Metabolic dysfunction-associated fatty liver disease (MAFLD) also known as non-alcoholic fatty liver disease (NAFLD), is one of the most prevalent liver diseases worldwide with high prevalence and economic burden, which affects 25% of global adult population. Despite extensive research on understanding the inner pathophysiology of MAFLD, it still keep growing with no approval therapy. Therefore, preventive measures are particularly important in diagnosing MAFLD. So far the liver biopsy is still the gold standard for diagnosis of MAFLD, however considering the invasive process and potential risks, it still has low acceptance for asymptomatic patients, thus non-invasive methods are necessary for this reason.
The purpose of this study is to establish a prediction model to identify MAFLD patients, which can accurately predict whether the participants have MAFLD according to the relevant metabolic indicators of the participants, without the need for invasive examinations such as tissue biopsy.
2,081 studies on the registry are indexed under Liver Diseases; 390 are open to participants now.
This study's planned enrollment of 500 is above the median of 167 across 681 observational studies indexed under Liver Diseases.
Browse Liver Diseases studies →The First Affiliated Hospital of Zhejiang Chinese Medical University is the lead sponsor of 37 studies on the registry; 18 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Chinese participants age 18 years or older diagnosed with MAFLD on imaging and healthy volunteers without MAFLD.
Exclusion Criteria:
MAFLD patients
health people
Area under cure
Area under cure(AUC) was defined as the area enclosed by the coordinate axis under the receiver operating characteristic curve, with values ranging from 0.5 to 1.0. The closer the AUC is to 1.0, the higher the authenticity of the detection method; the closer to 0.5, the lower the authenticity of the detection method; when equal to 0.5, the authenticity is the lowest and has no application value.
Time frame: 2022-2024
Accuracy
The proportion of the number of correctly classified samples to the total number of samples.
Time frame: 2022-2024
Precision
The proportion of data that is actually positive among the data that is determined to be positive.
Time frame: 2022-2024
This study is active, not recruiting, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The First Affiliated Hospital of Zhejiang Chinese Medical University